The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review.
An imbalance of oxidative-antioxidant defence mechanism has been proposed in systemic lupus erythematosus patients. Co-administration of N-acetylcysteine (NAC) which has a strong antioxidant activity may produce a satisfactory therapeutic outcome when added to standard therapy. We report a case of a 46-year-old lupus nephritis patient who received 1800 mg of NAC orally. After NAC, this patient showed a higher glutathione level, and a normal level of malondialdehyde, a lipid peroxidation product. In addition, the urinary protein levels, the complete blood counts and physical examination of the affected organs showed improvement. However, a well-controlled trial is needed to confirm the value of high-dose NAC in lupus nephritis patients.
Tewthanom
K
K
Faculty of Pharmacy, Silpakorn University, Thailand. karunrat@email.pharm.su.ac.th
Janwitayanujit
S
S
Totemchockcyakarn
K
K
Panomvana Na Ayudhya
D
D
D000111:Acetylcysteine / Q000008:administration & dosage* / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005978:Glutathione / Q000097:blood; D006801:Humans; D008181:Lupus Nephritis / Q000188:drug therapy*; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged
D000975:Antioxidants; D008315:Malondialdehyde; D005978:Glutathione; D000111:Acetylcysteine